Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR1093527

GTEX

0255f6f0-e40c-5f48-a188-f22bee4c8516

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
subtype
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.279
  • MYOGENESIS+0.201
  • SPERMATOGENESIS+0.090
  • UV_RESPONSE_UP+0.001
  • APICAL_SURFACE-0.024
  • MYC_TARGETS_V2-0.058
  • APICAL_JUNCTION-0.078
  • PI3K_AKT_MTOR_SIGNALING-0.085
  • MITOTIC_SPINDLE-0.100
  • HYPOXIA-0.104

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.576
  • INTERFERON_GAMMA_RESPONSE-0.472
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.424
  • TGF_BETA_SIGNALING-0.415
  • INFLAMMATORY_RESPONSE-0.370
  • NOTCH_SIGNALING-0.365
  • KRAS_SIGNALING_UP-0.364
  • OXIDATIVE_PHOSPHORYLATION-0.359
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.345
  • ANGIOGENESIS-0.344

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1379562
brain-umap@2
GTEX0.963
2SRR1479802
brain-umap@2
GTEX0.958
3SRR1348021
brain-umap@2
GTEX0.956
4SRR1413414
brain-umap@2
GTEX0.955
5SRR1434250
brain-umap@2
GTEX0.955
6SRR1434271
brain-umap@2
GTEX0.952
7SRR1467813
brain-umap@2
GTEX0.952
8SRR1388504
brain-umap@2
GTEX0.948
9SRR1453214
brain-umap@2
GTEX0.947
10SRR1431366
brain-umap@2
GTEX0.946

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 4 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.279Remibrutinib— uncovered
MYOGENESIS0.201Inavolisib— uncovered
SPERMATOGENESIS0.090Inavolisib— uncovered
UV_RESPONSE_UP0.001Idelalisib— uncovered